Neoadjuvant immunotherapy across cancers: meeting report from the Immunotherapy Bridge—December 1st–2nd, 2021

Neoadjuvant immunotherapy across cancers: meeting report from the Immunotherapy Bridge—December 1st–2nd, 2021

Abstract After the success of immunotherapy in the treatment of advanced metastatic cancer, further evaluation in earlier settings, including high-risk, surgically-resectable disease is underway. Potential benefits of a neoadjuvant immunotherapeutic approach include presurgical tumor shrinkage, redu...

Full description

Bibliographic Details
Main Authors: Elizabeth M. Burton, Rodabe N. Amaria, Tina Cascone, Myriam Chalabi, Neil D. Gross, Elizabeth A. Mittendorf, Richard A. Scolyer, Padmanee Sharma, Paolo A. Ascierto
Format: Article
Language:English
Published: BMC 2022-06-01
Series:Journal of Translational Medicine
Subjects:
Immunotherapy
Checkpoint inhibitors
PD-1
CTLA-4
Neoadjuvant
Pathological response
Online Access:https://doi.org/10.1186/s12967-022-03472-x

Internet

https://doi.org/10.1186/s12967-022-03472-x

Similar Items